PI-RADS v2.1 and PSAD for the prediction of clinically significant prostate cancer among patients with PSA levels of 4–10 ng/ml https://www.nature.com/articles/s41598-024-57337-y
Discover the world at Altruu, The Discovery Engine
PI-RADS v2.1 and PSAD for the prediction of clinically significant prostate cancer among patients with PSA levels of 4–10 ng/ml https://www.nature.com/articles/s41598-024-57337-y